NCT05969119View on ClinicalTrials.gov

Addition of Pyridostigmine to Conventional Management of Postdural Puncture Headache

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

January 3, 2024

Study Completion Date

January 3, 2024

Conditions
Postdural Puncture Headache
Interventions
DRUG

Pyridostigmine

Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.

DRUG

Placebo

Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.

Trial Locations (1)

Unknown

Suez General Hospital, Suez

All Listed Sponsors
lead

Ain Shams University

OTHER